Jiangsu Nhwa Osaino Biopharmaceutical

Jiangsu Nhwa Osaino Biopharmaceutical is the innovative research and development subsidiary of Jiangsu Nhwa Pharmaceutical, a leading Chinese pharmaceutical company specializing in Central Nervous System (CNS) therapeutics. The company focuses on the discovery and development of novel small molecules and biologics for anesthesia, analgesia, psychiatry, and neurology. Nhwa Osaino manages a diverse pipeline that includes internally developed candidates and high-profile licensed assets from international partners such as Trevena and Paion. By leveraging advanced R&D centers in Xuzhou and Shanghai, the company aims to address significant unmet medical needs in mental health and perioperative care. It serves as the primary vehicle for Nhwa's strategic transition from a generic manufacturer to an innovation-driven biopharmaceutical leader.